SHAPE

Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference

Retrieved on: 
Friday, March 8, 2024

BOTHELL, Wash., March 08, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented new clinical and preclinical data further highlighting the therapeutic potential of fosgonimeton at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, being held in Lisbon, Portugal March 5 – 9, 2024.

Key Points: 
  • Fosgonimeton is a potentially first-in-class investigational small molecule designed to positively modulate the hepatocyte growth factor (HGF) system, which can activate neuroprotective, neurotrophic and anti-inflammatory pathways in the central nervous system.
  • “We believe safety and efficacy outcomes from the exploratory SHAPE Phase 2 clinical trial presented at this year’s AD/PD, along with previous clinical data, support the continued development of fosgonimeton.
  • These findings support the potential therapeutic benefit of modulating the neurotrophic HGF system with fosgonimeton for neurodegenerative diseases.
  • “We’re pleased to be presenting additional preclinical data highlighting the neuroprotective effects of fosgonimeton in models of both Alzheimer’s and Parkinson’s diseases at AD/PD 2024,” said Kevin Church, Ph.D., Chief Scientific Officer of Athira.

IMCAS 2024: Galderma to Present Latest Updates From Its Unparalleled Aesthetics Portfolio Reinforcing Its Leadership Position

Retrieved on: 
Thursday, January 25, 2024

Galderma will be sharing the latest updates from across its broad and unparalleled portfolio at the International Master Course on Aging Science (IMCAS) World Congress 2024 from February 1-3, 2024, in Paris.

Key Points: 
  • Galderma will be sharing the latest updates from across its broad and unparalleled portfolio at the International Master Course on Aging Science (IMCAS) World Congress 2024 from February 1-3, 2024, in Paris.
  • The updates reinforce Galderma’s leadership in aesthetic injectables and dermatological skincare.
  • “The breadth of our data and activities at IMCAS truly embodies our commitment to responding directly to the needs of healthcare professionals and patients.
  • Three symposia will highlight Galderma’s innovations and science as well as educational efforts to support the aesthetics community.

Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update

Retrieved on: 
Monday, January 8, 2024

BOTHELL, Wash., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today provided a clinical pipeline outlook and business update for 2024. 

Key Points: 
  • BOTHELL, Wash., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today provided a clinical pipeline outlook and business update for 2024.
  • Athira’s 2024 Clinical Pipeline Outlook: Status and Upcoming Milestones
    Athira’s drug development pipeline consists of potential first-in-class (fosgonimeton) and next-generation small molecule therapeutic candidates (ATH-1105 and ATH-1020) designed to promote the neurotrophic HGF system, which activates neuroprotective, neurotrophic and anti-inflammatory pathways in the central nervous system.
  • In January 2024, Athira announced completion of enrollment in the LIFT-AD study, ultimately randomizing approximately 315 patients in the primary analysis population.
  • Hans Moebius, MD, PhD, is retiring as Chief Medical Officer effective January 5, 2024, and will continue as Athira’s Senior Scientific Advisor.

Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

Retrieved on: 
Wednesday, January 3, 2024

BOTHELL, Wash., Jan. 03, 2024 (GLOBE NEWSWIRE) --  Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced completion of enrollment in the Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease.  

Key Points: 
  • “The successful completion of enrollment in LIFT-AD marks an important milestone for Athira and enables the topline data readout in the second half of 2024,” said Mark Litton, Ph.D., President and Chief Executive Officer of Athira.
  • We also recently reported findings from the exploratory SHAPE Phase 2 clinical trial, which investigated the use of fosgonimeton in patients with Parkinson’s disease dementia and dementia with Lewy Bodies.
  • The results showed positive effects on several cognitive measures in the fosgonimeton 40 mg dose group, which is the same dose being investigated in the LIFT-AD trial.
  • The Phase 2/3 LIFT-AD clinical trial, which targeted an enrollment of 298 patients in the primary analysis population, ultimately enrolled approximately 315 patients with mild-to-moderate Alzheimer’s disease in a 26-week, randomized, double-blind, placebo-controlled clinical trial evaluating once-daily subcutaneous injections of fosgonimeton 40 mg compared to placebo.

Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

Retrieved on: 
Tuesday, December 12, 2023

BOTHELL, Wash., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced findings from the exploratory SHAPE Phase 2 clinical trial to evaluate fosgonimeton (ATH-1017) in patients with Parkinson’s disease dementia and dementia with Lewy Bodies.

Key Points: 
  • Fosgonimeton is a potentially first-in-class, investigational, small molecule designed to positively modulate the hepatocyte growth factor (HGF) system, which can activate neuroprotective, neurotrophic and anti-inflammatory pathways in the central nervous system.
  • In addition, directional improvements in other cognitive, functional and biomarker measurements were observed in the fosgonimeton 40 mg treatment group.
  • The most common adverse event in the treatment groups was injection site reactions.
  • “More broadly, we are encouraged by the clinical and preclinical evidence that support the potential therapeutic effects of HGF system positive modulation across a wide range of neurodegenerative diseases.”

All Kids Bike Receives $360,000 From HDR Foundation

Retrieved on: 
Thursday, September 7, 2023

“HDR and All Kids Bike have a shared vision to shape communities and empower future generations,” said Lisa Weyer, executive director of the Strider Education Foundation, the nonprofit that operates All Kids Bike.

Key Points: 
  • “HDR and All Kids Bike have a shared vision to shape communities and empower future generations,” said Lisa Weyer, executive director of the Strider Education Foundation, the nonprofit that operates All Kids Bike.
  • We’re incredibly grateful to HDR Foundation for its support.”
    It’s the second grant to All Kids Bike from the HDR Foundation.
  • This year’s grant is the largest given by the HDR Foundation and largest single gift received by All Kids Bike.
  • The HDR Foundation grant will bring the program to schools in the following communities during the 2023-2024 school year:

Global Military Aircraft MRO Market Set to Expand with Aging Fleets and Technological Advancements to 2031

Retrieved on: 
Friday, August 25, 2023

GLOBAL SHAPE MEASURING DEVICES MARKET, BY TYPE, 2021-2031 ($MILLION)

Key Points: 
  • GLOBAL SHAPE MEASURING DEVICES MARKET, BY TYPE, 2021-2031 ($MILLION)
    TABLE 02.
  • GLOBAL SHAPE MEASURING DEVICES MARKET, BY APPLICATION, 2021-2031 ($MILLION)
    TABLE 06.
  • GLOBAL SHAPE MEASURING DEVICES MARKET, BY SALES CHANNEL, 2021-2031 ($MILLION)
    TABLE 10.
  • NORTH AMERICA SHAPE MEASURING DEVICES MARKET, BY SALES CHANNEL, 2021-2031 ($MILLION)
    TABLE 16.

All Kids Bike® Announces the Activation of Its 1,000th Kindergarten Learn-To-Ride PE Program

Retrieved on: 
Tuesday, June 27, 2023

RAPID CITY, S.D., June 27, 2023 (GLOBE NEWSWIRE) -- All Kids Bike today announced the 1,000th delivery of its Kindergarten Learn-to-Ride PE Program at Geyser Road Elementary School, a Title I school in Saratoga Springs, N.Y.

Key Points: 
  • RAPID CITY, S.D., June 27, 2023 (GLOBE NEWSWIRE) -- All Kids Bike today announced the 1,000th delivery of its Kindergarten Learn-to-Ride PE Program at Geyser Road Elementary School, a Title I school in Saratoga Springs, N.Y.
  • This achievement marks a notable milestone for All Kids Bike, which is on a mission to teach every child in America how to ride a bike in Kindergarten PE class.
  • All Kids Bike projects more than 1 million children will have learned how to ride through its program by the end of 2027.
  • To donate to one of them, nominate a school for the All Kids Bike Kindergarten Learn-to-Ride PE Program, or learn how to bring the program to your local school district, please visit allkidsbike.org.

Brooks Running races into Q1 with 20% revenue growth

Retrieved on: 
Wednesday, May 3, 2023

After a record 2022, Brooks Running carried momentum into the first quarter of 2023 with 20% year-over-year global revenue growth, including a record 32% increase in the Europe, Middle East, and Africa (EMEA) region.

Key Points: 
  • After a record 2022, Brooks Running carried momentum into the first quarter of 2023 with 20% year-over-year global revenue growth, including a record 32% increase in the Europe, Middle East, and Africa (EMEA) region.
  • In direct e-commerce, Brooks’ Q1 global revenue grew 33% year over year.
  • Brooks and parkrun are working together to foster continual growth of the global running community.
  • Timed to Boston, Brooks launched the first-ever Des x Run Boston collection, designed in collaboration with Brooks’ Chief Running Advisor Des Linden to celebrate the five-year anniversary of her 2018 Boston Marathon win.

KMT Waterjet Systems Names Brendan Shackelford as New President

Retrieved on: 
Monday, May 1, 2023

BAXTER SPRINGS, Kan., May 1, 2023 /PRNewswire/ -- KMT Waterjet Systems, the leading global manufacturer of ultrahigh-pressure waterjet pumps and components used in complete waterjet systems, today announced that Brendan Shackelford, current President of Shape Technologies Waterblast Group, has been named the new President of KMT Waterjet Systems.

Key Points: 
  • BAXTER SPRINGS, Kan., May 1, 2023 /PRNewswire/ -- KMT Waterjet Systems, the leading global manufacturer of ultrahigh-pressure waterjet pumps and components used in complete waterjet systems, today announced that Brendan Shackelford, current President of Shape Technologies Waterblast Group, has been named the new President of KMT Waterjet Systems.
  • Shackelford joined the SHAPE organization in November 2016 as Aftermarket Director for the Shape Waterblast Group and assumed the leadership role in January 2018.
  • "I have been impressed with the development and technological advancements made with waterjet systems and am excited to join KMT Waterjet, a company known for their history of innovation and contribution to this industry," said Shackelford.
  • "As we look to the future and building upon our success at KMT Waterjet, I couldn't think of a more qualified individual to fill this role than Brendan," said Nino LaDuca, CEO of Shape Technologies Group.